EUVIMEDEUVIMED entdecken
Open Access

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

Adriana Hepner, Judith M Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojaniello, Camille Lea Gerard, Yanina Jl Jansen, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin und 16 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2023.113441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Adriana Hepner und 27 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia, The University of Sydney, NSW, Australia; Instituto do Cancer do Estado de Sao Paulo, SP, Brazil. Hauptthemen laut MEDLINE: Melanoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Melanoma Institute Australia, National Computational Infrastructure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaHumansMiddle AgedCTLA-4 AntigenImmunotherapyRetrospective StudiesAntibodiesProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

Cytotoxic T-Lymphocyte Antigen 4Disease ProgressionImmunotherapyMelanomaProgrammed death-1Resistance

Substanzen

CTLA-4 AntigenAntibodiesPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Melanoma Institute Australia, The University of Sydney, NSW, Australia; Instituto do Cancer do Estado de Sao Paulo, SP, Brazil.
  • Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands.
  • Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Australia.
  • Université Paris Cite, Dermato-Oncology AP-HP Hôpital Saint Louis, INSERM U976, F-75010 Paris, France.
  • Crown Princess Mary Cancer Centre Westmead and Blacktown Hospitals, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.

Förderung

  • NCI NIH HHS
  • Melanoma Institute Australia
  • National Computational Infrastructure
  • Nicholas and Helen Moore and Melanoma Institute Australia
  • National Health and Medical Research Council
  • Conquer Cancer Foundation
  • University of Sydney

Zitieren

APA

Hepner, A., Versluis, J. M., Wallace, R., Allayous, C., Brown, L. J., Trojaniello, C., Gerard, C. L., Jansen, Y. J., Bhave, P., Neyns, B., Haydon, A., Michielin, O., Mangana, J., Klein, O., Shoushtari, A. N., Warner, A. B., Ascierto, P. A., McQuade, J. L., Carlino, M. S., …, & Menzies, A. M. (2024). The features and management of acquired resistance to PD1-based therapy in metastatic melanoma. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.113441

Vancouver

Hepner A, Versluis JM, Wallace R, Allayous C, Brown LJ, Trojaniello C, et al. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2023.113441

BibTeX
@article{Hepner2024,
  author = {Hepner, Adriana and Versluis, Judith M and Wallace, Roslyn and Allayous, Clara and Brown, Lauren Julia and Trojaniello, Claudia and Gerard, Camille Lea and Jansen, Yanina Jl and Bhave, Prachi and Neyns, Bart and Haydon, Andrew and Michielin, Olivier and Mangana, Joanna and Klein, Oliver and Shoushtari, Alexander N and Warner, Allison Betof and Ascierto, Paolo Antonio and McQuade, Jennifer Leigh and Carlino, Matteo S and Zimmer, Lisa and Lebbe, Celeste and Johnson, Douglas B and Sandhu, Shahneen and Atkinson, Victoria and Blank, Christian U and Lo, Serigne N and Long, Georgina V and Menzies, Alexander M},
  title = {The features and management of acquired resistance to PD1-based therapy in metastatic melanoma},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2023.113441}
}
Kostenlos starten →